Tumor debulking combined with standard first-line palliative chemotherapy does not improve survival outcomes for patients with multiorgan metastatic colorectal cancer compared to chemotherapy alone, according to a study published in JAMA on Mar. 19.
This finding is significant because colorectal cancer remains one of the most commonly diagnosed cancers worldwide and a leading cause of cancer-related deaths. Many patients eventually develop metastatic disease, which is associated with poor outcomes. The role of aggressive local treatments such as surgical resection and thermal ablation has been established for patients with limited metastases, but their benefit in more extensive disease has remained uncertain.
The ORCHESTRA trial, a randomized phase 3 clinical study involving 382 patients—most treated at hospitals in the Netherlands—sought to determine if adding tumor debulking to chemotherapy would increase overall survival by at least six months. All participants had tumors that could be reduced by at least 80 percent before starting first-line palliative chemotherapy. After initial treatment, those who responded or had stable disease were randomized to receive either continued chemotherapy alone or chemotherapy plus debulking.
Results showed no significant difference in overall or progression-free survival between the two groups. However, serious adverse events were higher among those receiving debulking (53 percent) compared to those on chemotherapy alone (39 percent). Quality-of-life outcomes were similar across both groups. Fewer patients in the debulking group completed at least six months of chemotherapy, possibly due to disease progression during local therapy or challenges resuming systemic treatment after surgery.
Subgroup analyses did not show a survival benefit for patients with liver- or lung-limited metastases, though the trial was not designed to definitively assess these smaller groups. The authors noted that while an exploratory analysis suggested some benefit among patients with stable disease at randomization, this was not supported by improved progression-free survival and thus may lack clinical significance.
The study's conclusions are tempered by limitations such as its ten-year recruitment period and use of older chemotherapy regimens; however, both arms experienced these factors equally and survival rates matched recent trials. "These results highlight the importance of prospective randomized clinical trials when considering the role of local therapies in the treatment of patients with mCRC," the authors said.
The findings suggest that routine use of tumor debulking alongside systemic chemotherapy should not be recommended for multiorgan metastatic colorectal cancer.
